U.S. Supreme Court temporarily restores broad access to abortion pill mifepristone

On a Monday in Washington, the Supreme Court moved to undo what a lower court had just done. Justice Samuel Alito signed an order that restored broad access to mifepristone, the abortion pill that has become the dominant method for ending pregnancies across the United States. The decision blocked a federal appeals court ruling from the previous week that would have imposed new restrictions on how the drug could be prescribed and delivered. For now, women seeking to end a pregnancy can obtain mifepristone through pharmacies or by mail without visiting a doctor in person—a practice that had been permitted for years before the appeals court intervened.

The order is temporary. It will remain in effect for one week while both sides file additional arguments and the Supreme Court takes more time to consider the case fully. But that week matters enormously to the people and organizations caught in the middle of this legal ping-pong. Most abortions in the United States are now accomplished with medication rather than surgical procedures. Since the Supreme Court overturned Roe v. Wade in 2022, erasing the constitutional right to abortion that had stood for nearly fifty years, Democratic-led states have moved to protect doctors who prescribe abortion pills remotely to patients in states where the procedure is banned. A recent analysis found that in the thirteen states with total abortion bans, more women obtained medication abortions through telemedicine last year than traveled to other states to have the procedure done. Those remote prescriptions have become a crucial workaround to the restrictions that Republican-led states have rushed to implement.

Louisiana brought the lawsuit challenging the FDA's rules for prescribing mifepristone, arguing that the agency's policy undermines the state's abortion ban. The case also questioned whether the drug is safe—a question the FDA has answered repeatedly over the past twenty-five years, consistently finding it both safe and effective. This lawsuit represents the most advanced of several efforts by abortion opponents to restrict access to mifepristone. Mifepristone is typically taken alongside a second drug, misoprostol, and according to the FDA label, this combination completes a medical abortion ninety-seven point four percent of the time. Misoprostol alone can also be used to end pregnancies, with some studies showing effectiveness rates around eighty percent or higher. In countries where mifepristone is prohibited or unavailable, misoprostol is often used by itself. The difference matters: misoprostol has never been formally approved by the FDA for abortion, though doctors have adapted it for that purpose. Because the FDA never authorized it for ending pregnancies, it has faced far less scrutiny from pro-life groups.

When the appeals court ruling came down, several organizations that prescribe abortion pills remotely scrambled over the weekend to switch to misoprostol alone—a regimen that can cause more prolonged side effects. Dr. Angel Foster, who founded The Massachusetts Abortion Access Project, said her organization was prepared to send only misoprostol by Monday afternoon, but the Supreme Court's order allowed them to return to the two-drug combination. "Regardless of what happens with this regulatory matter, we and other organizations will continue providing high-quality abortion care to patients in all fifty states," she said. Julie Burkhart, founder of Wellspring Health Access, a clinic in Wyoming that performs roughly one hundred medication abortions per year through remote prescriptions, noted that the temporary suspension gives them time to navigate the shifting landscape.

The rapid-fire rulings created confusion that rippled through the system. Foster's organization spent the weekend orienting different groups of patients: those who had been sent mifepristone but had not yet received it; those approved for the drugs but had not paid or had not had them shipped; and those making initial requests. For now, they are asking patients to approve shipment of pills with or without mifepristone, in case another change comes. Elizabeth Ling, associate director of legal services at If/When/How, which provides guidance to women considering abortion, offered perspective on what comes next: "The result is not going to make it a crime for people to access care." She was right. None of the state laws currently include any punishment for women who have abortions.

Pro-life groups made clear they intend to keep fighting. Carol Tobias, president of National Right to Life, called the Monday ruling "a temporary procedural step" that leaves unresolved "very real concerns about the safety of these drugs." Louisiana's attorney general, Liz Murrill, who filed the lawsuit alongside a woman claiming her boyfriend coerced her into taking abortion pills, went further, attacking pharmaceutical companies for their role in the case. "The big abortion pharmaceutical industry claims it needs an emergency suspension because it will lose enormous amounts of money if it cannot kill more babies quickly and efficiently by mail without medical supervision," Murrill said. "The administrative suspension is temporary, and I am confident that life and the law will prevail in the end." The battle, in other words, is far from over. The Supreme Court has bought time, but the fundamental question—whether mifepristone will remain accessible to American women—remains unresolved.